Alliancebernstein L.P. lowered its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 258,798 shares of the life sciences company’s stock after selling 5,307 shares during the period. Alliancebernstein L.P. owned about 0.18% of Illumina worth $56,545,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in the company. Financial Gravity Companies Inc. bought a new position in Illumina during the fourth quarter worth $106,000. Dupont Capital Management Corp bought a new position in Illumina during the third quarter worth $153,000. SeaCrest Wealth Management LLC bought a new position in Illumina during the fourth quarter worth $154,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in Illumina by 113.9% during the fourth quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock worth $168,000 after buying an additional 410 shares during the last quarter. Finally, Patten Group Inc. raised its stake in Illumina by 71.1% during the third quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock worth $172,000 after buying an additional 615 shares during the last quarter. 91.51% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts recently weighed in on the stock. BidaskClub raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday. Citigroup raised shares of Illumina from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $260.00 to $275.00 in a research note on Monday, February 5th. Barclays lifted their target price on shares of Illumina from $200.00 to $215.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 31st. Morgan Stanley lifted their target price on shares of Illumina from $145.00 to $157.00 and gave the stock an “underweight” rating in a research note on Wednesday, January 31st. Finally, Leerink Swann lifted their target price on shares of Illumina from $250.00 to $276.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have assigned a buy rating to the company. Illumina presently has a consensus rating of “Buy” and an average price target of $241.39.
Shares of Illumina, Inc. (NASDAQ ILMN) opened at $253.17 on Tuesday. The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.43. The company has a market cap of $37,220.00, a price-to-earnings ratio of 42.62, a price-to-earnings-growth ratio of 3.31 and a beta of 0.93. Illumina, Inc. has a twelve month low of $158.02 and a twelve month high of $254.89.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.22. The business had revenue of $778.00 million during the quarter, compared to analysts’ expectations of $752.04 million. Illumina had a net margin of 26.56% and a return on equity of 21.71%. The business’s quarterly revenue was up 25.7% on a year-over-year basis. During the same period last year, the company posted $0.85 earnings per share. equities analysts predict that Illumina, Inc. will post 4.59 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Alliancebernstein L.P. Has $56.55 Million Stake in Illumina, Inc. (ILMN)” was originally reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/03/13/alliancebernstein-l-p-has-56-55-million-stake-in-illumina-inc-ilmn.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.